A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zoledronate (4 and 8 mg) Administered Intravenously as an Adjuvant to Anticancer Therapy to Patients With Any Cancer With Bone Metastases Other Than Breast Cancer, Multiple Myeloma or Prostate Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jan 2010
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Cancer metastases; Lung cancer; Solid tumours
- Focus Registrational; Therapeutic Use
- 17 Sep 2005 New trial record.